One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage All Access membership.
Explore Editage All Accesshttps://doi.org/10.1016/s0090-8258(22)01541-4
Copy DOI Journal: Gynecologic Oncology |  Publication Date: Aug 1, 2022 |
Affiliation: Mersana Therapeutics (United States), Centre Léon Bérard, Rigshospitalet, The US Oncology Network, University of Oklahoma Health Sciences Center, New York University Langone Medical Center, Arizona Oncology, University of Arizona, Creighton University, Kliniken Essen-Mitte, Universität InnsbruckOptimizing the dose of upifitamab rilsodotin (UpRi; XMT-1536), a NaPi2b-directed dolaflexin antibody drug conjugate (ADC): A posthoc analysis of a phase 1b expansion study in ovarian cancer (319)
Sign-in/Register to access full text options 
Free) Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
